News

Reduced risk of RA in schizophrenia may be bias, not biology


 

FROM SCHIZOPHRENIA BULLETIN

The observed reduced risk of rheumatoid arthritis and osteoarthritis in patients with schizophrenia might be tied to reporting bias rather than disease-specific biology, Dr. Carl Sellgren and colleagues reported.

Data on more than 6 million people contained in the Swedish Population Register showed significantly reduced risks of both disorders, and of other musculoskeletal diseases, among schizophrenia patients, wrote Dr. Sellgren of the Karolinksa Institute, Stockholm, and his associates. Conversely, no increased risks were found among patients with bipolar disorder, despite a shared polygenic component of 68% between the two mental illnesses (Schizophr. Bull. 2014 Apr. 8 [doi:10.1093/schbul/sbu054]).

"In light of the more severe loss of function in schizophrenia and schizoaffective disorder patients in comparison to bipolar disease patients, this is compatible with differential misclassification bias in the observed inverse association between schizophrenia and rheumatoid arthritis," the researchers wrote.

Dr. Sellgren and his team were not ready to entirely scrap the possibility of some biologic link, however.

"Interestingly, we observed a significantly decreased risk for seronegative RA in children and siblings of schizophrenia probands," he said in an interview. "Correspondingly, the lowest point estimate for schizophrenia was observed in relatives of seronegative RA patients, and the lowest point estimate among schizophrenia patients was also observed for seronegative RA. Genetic causation may be present regarding the specific association between schizophrenia and seronegative RA."

Whatever the link, the study points up the importance of looking at schizophrenia patients holistically, rather than only focusing on their mental illnesses. "It appears that the more severely affected the patient is of the psychiatric disorder, the less likely is the clinician to identify a comorbid musculoskeletal disease," he said. "These data emphasize the need of assessing and being aware of nonpsychiatric symptoms in schizophrenia."

The Swedish Medical Research Council funded the study. Dr. Sellgren made no financial disclosures.

msullivan@frontlinemedcom.com

On Twitter @Alz_Gal

Recommended Reading

Smoking rate among people with mental illness shows negligible decline
MDedge Internal Medicine
Smoking cessation maintained with varenicline plus CBT
MDedge Internal Medicine
Health care reform may cut behavioral admissions
MDedge Internal Medicine
High-yield techniques in brief CBT sessions can promote adherence
MDedge Internal Medicine
Pharmacist discovery spurs recall of extended-release venlafaxine
MDedge Internal Medicine
Personal health records help mentally ill patients with comorbidities access medical services
MDedge Internal Medicine
Hoarding: Not just a symptom of OCD
MDedge Internal Medicine
Human brain mapping project begins to reveal roots of developmental abnormalities
MDedge Internal Medicine
Negative symptoms linked to poor functioning in schizophrenia
MDedge Internal Medicine
Biomarkers of vulnerability for schizophrenia identified in youth
MDedge Internal Medicine